A big year ahead exhausting all the cross selling opp between...

A big year ahead exhausting all the cross selling opp between cosamp, aiet and now ripponlea as well as all the direct schools. I'd love one more acquisition in the near term and then a sole focus on the cross selling for next season.

Based on my back of the envelope numbers we're going to go very close to break even EBITDA this FY. That in itself might be a catalyst for the sp seeing as new investors would come across the company at a time with siginificant cross selling opps and an aggressive strategy in the VET space.

Even with ~$6.5 in the bank, we need a float of about $4-5m to account for the receipt seasonality (& expected full curriculum growth) so there's every possibility that the next acquisition (should it be a $3-4m 'big one') would require a CR alongside it. Irrespective of the usual negative connotations associated with a CR, that would be one that would be welcomed

FY21 EBITDA looking like +-$300k or so for me